PKM2 was identified as a promising target for cancer therapy, with subcellular localization of PKM2 proposed as a potential biomarker for therapeutic response in non-small-cell lung cancer (NSCLC) cell lines [123]. The gene discussed is PKM; the disease is non-small cell lung carcinoma.